Mersana Therapeutics reports Q1 EPS (19c), consensus (19c)

Reports Q1 revenue $2.754M, consensus $6.05M. “Given recent positive front-line data reported from topo-1 ADC registrational trials, we believe the post-topo-1 breast cancer patient population is poised to expand significantly. Our initial aim is to develop Emi-Le to serve this high unmet need population,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics (MRSN). “To that end, we were pleased to present encouraging preliminary progression free survival and overall survival data for Emi-Le among patients with post-topo-1 TNBC today at ESMO Breast Cancer 2025. Additionally, our team has made considerable progress enrolling these patients in our dose expansion cohorts thus far in 2025, putting us on track for an initial expansion data readout later this year.”